Login
$AYTU
$2.61 +$0.79 (43.43%) After hours

$AYTU 8-K/A SEC Filings

Filed On Filing
21 May 2021 8-K/A: Financial Statements and Exhibits

Report of Independent Auditor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2

26 Feb 2020 8-K/A: Financial Statements and Exhibits

We hereby consent to the incorporation by reference in the Registration Statements (Form S-1 Nos 333-207421, 333-205414, 333-209874, 333-212100, 333-213489, 333-220351, Form S-3 Nos 333-221735, 333-235548, and Form S-8 No. 333-205462) of...

10 Jan 2020 8-K/A: Completion of Acquisition or Disposition of Assets

The following unaudited pro forma condensed combined financial information is presented to illustrate the estimated effects of the merger.

07 Nov 2019 8-K/A: Entry into a Material Definitive Agreement

This Consent and Limited Waiver Agreement (this “Waiver”) is entered into as of the November 1, 2019, by and among Peter Steelman (“Steelman”), James Flynn (“Flynn”), and Deerfield CSF, LLC, on behalf of itself and its affiliates (“Deerf...

04 Nov 2019 8-K/A: Financial Statements and Exhibits

This Consent and Limited Waiver Agreement (this “Waiver”) is entered into as of the November 1, 2019, by and among Peter Steelman (“Steelman”), James Flynn (“Flynn”), and Deerfield CSF, LLC, on behalf of itself and its affiliates (“Deerf...

31 Aug 2017 8-K/A: Results of Operations and Financial Condition

Englewood, CO – August 31, 2017 – Aytu BioScience, Inc. (OTCQX: AYTUD), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an overview of its business, includin...

20 Jul 2017 8-K/A: Financial Statements and Exhibits

As of March 31, 2017, and for the Nine Month Period Ended March 31, 2017

30 Jul 2015 8-K/A: Financial Statements and Exhibits

On May 20, 2015 Aytu BioScience, Inc. (the “Company”) (formerly Rosewind Corporation) consummated the previously announced purchase of certain assets and rights associated with ProstaScint® (the “Product”), and the sourcing, manufacture ...

08 Jun 2015 8-K/A: Other Events

*** CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATIO...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support